Press Release9 Aug 2024, 05:13 pm
Caplin Point Laboratories Ltd Recognized in Forbes Asia's '200 Best Under a Billion' for 2024
AI Summary
Caplin Point Laboratories Ltd, a fast-growing pharmaceutical company, has been recognized in Forbes Asia's '200 Best Under a Billion' list for the year 2024. This is the seventh time the company has been featured on this list, a rare achievement for an Indian pharmaceutical company. The company's unique business model caters predominantly to emerging markets of Latin America and Africa, and it has shown consistent high-quality growth in Revenues, Profits and Cash flow over the last 15 years. Caplin Point Laboratories Limited has state-of-the-art manufacturing facilities and has also entered regulated markets such as the US through its Subsidiary Caplin Steriles Limited.
Key Highlights
- Caplin Point Laboratories Ltd recognized in Forbes Asia's '200 Best Under a Billion' for 2024
- Seventh time appearance on the list, a rare achievement for an Indian pharmaceutical company
- Consistent high-quality growth in Revenues, Profits and Cash flow over the last 15 years
- State-of-the-art manufacturing facilities catering to a complete range of finished dosage forms
- Entered regulated markets such as the US through its Subsidiary Caplin Steriles Limited